Candidiasis — Mucosal and Invasive

Candidiasis represents infection caused by Candida species, predominantly Candida albicans, ranging from superficial mucosal disease to life-threatening invasive infection. The clinical significance derives from its dual nature: it represents the most common fungal infection in hospitalized patients and the most frequent opportunistic infection in HIV/AIDS patients with CD4+ counts <50 cells/μL. Incidence of invasive candidiasis has increased substantially over the past two decades, with candidemia occurring in approximately 5-15 cases per 100,000 hospital admissions in developed countries, and invasive disease carrying crude mortality rates of 30-50%. Candidiasis is critically important for clinical practice because its presentation varies dramatically by immune status and anatomic location, and early recognition with appropriate antimicrobial therapy significantly impacts outcomes. For board examinations, recognition of predisposing conditions, differentiation between mucosal and invasive disease, and knowledge of antifungal therapy represents high-yield material.

Candida albicans exists as normal commensal flora in the oral cavity, gastrointestinal tract, and genitourinary system in most healthy individuals. The organism exists in two morphologic forms: unicellular yeast (blastospores) and hyphal forms. The yeast form predominates during normal colonization, representing the less virulent phenotype. However, conversion to hyphal and pseudohyphal morphology—triggered by elevated temperature (37°C), elevated pH, serum components, and specific nutrient deprivation—characterizes pathogenic infection. This morphologic transition is mediated by upregulation of hyphal-specific genes including EFG1 and CPH1, which promote expression of adhesins and invasins. The hyphal form penetrates epithelial barriers, resists phagocytosis more effectively, and secrete tissue-damaging enzymes (aspartyl proteases, lipases, phospholipases). Progression from colonization to clinical infection requires either overwhelming fungal burden or immunosuppression that permits escape from normal host containment.

The primary defense against mucosal candidiasis is intact cellular immunity, particularly Th17-mediated responses involving IL-17 and IL-22, which promote production of antimicrobial peptides (β-defensins) by epithelial cells and enhance mucosal barrier function. In healthy individuals, CD4+ T cells recognize Candida antigens and coordinate protective immunity; loss of this function below CD4+ 50 cells/μL in HIV/AIDS patients or T-cell dysfunction from chemotherapy, corticosteroids, or TNF-α inhibitors eliminates this critical defense. Candida evades innate immunity through multiple mechanisms: the cell wall's β-glucan is masked by mannoproteins, preventing pattern recognition receptor engagement; the organism produces proteases that degrade complement and immunoglobulins; and hyphal forms physically penetrate epithelial surfaces, bypassing the mucus layer and epithelial tight junctions. In the setting of severe immunosuppression, particularly CD4+ <50 cells/μL, the organism disseminates through damaged epithelial barriers into the bloodstream, establishing candidemia and seeding target organs.

At the cellular level, Candida adheres to epithelial cells through fungal adhesins (Als1, Als3, Hwp1) binding to host cell receptors (E-cadherin, N-cadherin, integrins). Secreted aspartyl proteases (Sap1-10) degrade host cell proteins and junctional proteins, directly disrupting epithelial integrity. The hyphal form produces a specialized penetration structure that physically invades through epithelial cells, creating microabscesses and ulceration. In esophageal candidiasis, invasion through the squamous epithelium causes local inflammation with infiltration of polymorphonuclear leukocytes and macrophages, resulting in ulceration. The candidal cell wall contains pathogen-associated molecular patterns (PAMPs) including β-glucan and mannan that activate complement via the alternative pathway and engage TLR receptors, amplifying inflammatory responses. This inflammatory milieu paradoxically creates further epithelial damage while failing to clear the organism when cellular immunity is severely compromised.

Candida species form biofilms on biotic surfaces (catheter tips, prosthetic materials, dentures) and abiotic surfaces (epithelial cells, organ surfaces). Biofilm formation involves initial adhesion, followed by yeast-to-hyphal conversion, production of extracellular matrix (polysaccharides, proteins, lipids), and development of multicellular communities. Within biofilms, Candida exhibits dramatically increased resistance to antifungal agents—fluconazole resistance increases 100-1000 fold within biofilm architecture compared to planktonic cells. This occurs through multiple mechanisms: the biofilm matrix physically reduces drug penetration, upregulation of efflux pumps (CDR1, MDR1) increases drug extrusion, and altered cell wall composition reduces drug uptake. Biofilms also contain dormant yeast cells with reduced metabolic activity, rendering them less susceptible to cell wall-active agents. The presence of indwelling medical devices (central venous catheters, urinary catheters, prosthetic valves) predisposes to biofilm-associated candidemia that may be refractory to antifungal therapy without device removal.

In oropharyngeal candidiasis, Candida invades the stratified squamous epithelium, causing acute inflammatory response with pseudomembrane formation composed of desquamated epithelial cells, fibrin, and fungal elements. White plaques adhere to epithelium due to invaded hyphae; when scraped, they leave a red, bleeding surface. In esophageal candidiasis, the organism extends into the submucosa, causing ulceration and potential perforation. Dysphagia results from pain-mediated dysmotility and mucosal edema rather than mechanical obstruction. In vulvovaginal candidiasis, the organism proliferates in the acidic vaginal environment (pH 3.8-4.5), triggering an inflammatory response with recruitment of neutrophils and inflammatory mediators (IL-8, TNF-α), causing vulvar erythema, edema, and pruritus. In invasive candidiasis, hematogenous dissemination from a primary mucosal or cutaneous source seeds target organs; the kidneys and liver represent the most frequent sites due to high blood flow, but CNS involvement carries highest morbidity. Candida albicans exhibits tissue tropism partly determined by hyphal formation and expression of specific adhesins favoring particular organ environments.

Advanced HIV/AIDS with CD4+ count <50 cells/μL represents the most significant risk factor for invasive and severe mucosal candidiasis, affecting 50-95% of untreated patients at this immune threshold. The loss of Candida-specific CD4+ T cells eliminates Th17 responses critical for mucosal immunity, allowing explosive mucosal colonization and dissemination. Risk correlates directly with CD4+ count nadir—oral candidiasis becomes common at CD4+ <200 cells/μL, esophageal disease at CD4+ <50 cells/μL. Immune reconstitution with antiretroviral therapy (ART) restores this risk stratification. Candidemia in HIV patients indicates severely depressed immunity and high mortality if CD4+ remains <50 cells/μL despite treatment.

Systemic corticosteroids, particularly when used at high doses (≥20 mg prednisone daily equivalent) or for prolonged duration, impair both T-cell-mediated immunity and neutrophil chemotaxis and killing capacity. Inhaled corticosteroids significantly increase oropharyngeal candidiasis risk through direct local immunosuppression of the oral mucosa and reduced local IgA production. The risk is dose-dependent and partially reversible upon steroid tapering. Patients using inhaled corticosteroids can substantially reduce candidiasis risk by rinsing the mouth after inhalation to prevent local drug deposition.

Chemotherapy-induced neutropenia (neutrophil count <500 cells/μL) dramatically increases invasive candidiasis risk; patients with hematologic malignancies undergoing induction therapy experience neutropenic periods of 1-3 weeks where disseminated candidiasis risk increases substantially. Acute leukemia patients with prolonged chemotherapy-induced neutropenia and those undergoing allogeneic bone marrow transplantation (BMT) have invasive candidiasis rates of 5-25%, with risk extending throughout the period of neutrophil recovery. Additionally, chemotherapy damages the epithelial barrier of the GI tract, providing a portal of entry for translocation of candidal organisms from the lumen into the bloodstream.

Central venous catheters represent the most common predisposing factor for candidemia in hospitalized patients, accounting for 40-60% of cases in non-neutropenic patients. Risk increases with catheter duration >7-10 days, with longer-term catheters (weeks to months) in dialysis, parenteral nutrition, or chemotherapy patients carrying substantial risk. Catheters provide a surface for biofilm formation and allow direct access to the bloodstream. The absolute attributable risk of candidiasis increases with number of lumens, catheter material (polyvinyl chloride > silicone), and presence of concurrent bacteremia.

Antibiotic therapy, particularly with broad-spectrum agents (fluoroquinolones, cephalosporins, carbapenems), disrupts normal bacterial flora that competitively inhibit Candida overgrowth in the GI tract. The loss of normal microbiota permits exponential Candida proliferation. Prolonged antibiotic exposure >7-10 days substantially increases risk, particularly when antibiotics are continued despite negative bacterial cultures.

Critically ill patients in the ICU experience multiple synergistic risk factors: disrupted GI barriers from stress ulceration, hypotension, medications that alter gastric pH (proton pump inhibitors, H2-blockers), sedatives that impair mucosal function, and mechanical ventilation that eliminates oral hygiene. Abdominal surgery, particularly GI surgery, creates direct breaches in the epithelial barrier and may introduce intestinal candida into the peritoneal cavity or bloodstream. Post-operative candidemia risk is highest when surgery is followed by peritonitis, anastomotic leak, or sepsis.

Uremia impairs immune function through multiple mechanisms: uremic toxins inhibit T-cell proliferation, neutrophil chemotaxis is reduced, and complement activation is decreased. Dialysis patients have additional risk from vascular access complications, frequent hospitalizations, and cumulative CVC exposure.

Dentures and poor oral hygiene predispose to denture stomatitis (chronic atrophic candidiasis under dentures). Oral antibiotics or topical corticosteroids in the mouth increase oropharyngeal disease risk. Diabetes mellitus increases vulvovaginal candidiasis risk through hyperglycemia-induced osmotic diuresis creating glycosuria, which promotes Candida proliferation in the vaginal environment and impairs local neutrophil function. Pregnancy increases vulvovaginal disease risk through hormonal changes (increased estrogen) that alter vaginal pH and increase glycogen availability.

Genetic polymorphisms affecting IL-17 signaling (STAT3, IL-17 receptor mutations) and defects in T-cell receptor excision circles (TRECs) predispose to chronic mucocutaneous candidiasis (CMC), a rare condition with recurrent/persistent mucosal candidiasis despite normal CD4 counts. Similarly, patients with AIRE gene mutations (autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy, APECED) develop severe candidiasis due to T-cell dysfunction.

The most common presentation of mucosal candidiasis manifests as white, adherent plaques on the buccal mucosa, hard palate, tongue, or pharynx. These plaques consist of fungal hyphae, desquamated epithelial cells, and fibrin; they adhere firmly to underlying erythematous mucosa, and scraping reveals a bleeding red surface (distinguishing them from oral leukoplakia, which is non-scrapable). Patients report discomfort or burning sensation proportional to degree of invasion, though many patients describe only mild symptoms or are asymptomatic until lesions extend to the pharynx. Taste alteration commonly occurs due to involvement of taste buds. Some patients present with erythematous candidiasis (atrophic form) with beefy red mucosa lacking white plaques, particularly common in denture wearers. Angular cheilitis (candidal infection of mouth corners) presents as cracks or fissures at the commissures. In severe cases with extensive pharyngeal involvement, patients may experience dysphagia and difficulty with oral intake.

This represents invasive mucosal disease with deeper epithelial penetration and more severe symptoms. Patients present with odynophagia (painful swallowing) as the cardinal symptom, often more prominent than dysphagia. Odynophagia is pathognomonic for esophageal involvement, distinguishing it from mechanical obstruction. Patients may report substernal chest pain or epigastric discomfort. Dysphagia occurs due to mucosal edema and motility dysfunction rather than luminal obstruction. Some patients report nausea and vomiting from esophageal irritation. Systemic symptoms including low-grade fever and malaise may accompany severe disease. In immunocompromised patients with CD4+ <50 cells/μL, esophageal candidiasis may progress to severe ulceration with risk of perforation. Bleeding occurs rarely but indicates deep mucosal ulceration. Physical examination is typically unremarkable; diagnosis is endoscopic. The condition frequently co-exists with oropharyngeal candidiasis (75-90% of esophageal disease cases), though esophagitis can occur without visible oral disease.

This represents the most common form of mucosal candidiasis in non-immunocompromised women, affecting 75% of women at least once in their lifetime. Vulvar pruritus is the most prominent symptom, often severe enough to cause sleep disruption and significant distress. Vulvar burning or irritation accompanies itching. Vaginal discharge is characteristically thick, white, curd-like, and adherent to vaginal walls; it lacks the offensive odor of bacterial vaginosis and has neutral-to-acidic pH. Dyspareunia (painful intercourse) occurs from vulvar inflammation and occasionally dysuria (external dysuria from contact of urine with inflamed vulvar tissue). Vulvar erythema and edema are visible on examination, often with satellite erythema extending beyond the primary area. Vaginal erythema with petechial hemorrhages may be visible on speculum examination. In complicated VVC (involving the vaginal wall, severe symptoms, or recurrent disease), vaginal wall ulcerations and fissuring occur. Systemic symptoms are absent unless secondary bacterial infection occurs.

Patients with candidemia present with persistent fever (often >38.5°C) unresponsive to antibiotics, representing the most common presentation in hospitalized patients. Fever may be accompanied by chills and rigors with hemodynamic instability in severe sepsis. Importantly, candidemia may present with minimal specific symptoms beyond fever, making diagnosis particularly challenging. Some patients develop septic shock with hypotension, altered mental status, and multiorgan dysfunction. The absence of localizing symptoms is typical; patients may have no pulmonary, urinary, or abdominal symptoms despite bloodstream infection. Thrombocytopenia develops in 30-50% of candidemia cases due to bone marrow infiltration by candidal organisms and inflammatory cytokine effects. Elevated transaminases and bilirubin indicate hepatic involvement, while renal dysfunction suggests renal candidiasis. Some patients develop skin manifestations with erythematous macules or nodules (resembling bacterial sepsis) that may contain candidal organisms on biopsy. In disseminated disease, eye involvement (Candida endophthalmitis) presents as floaters, blurred vision, or visual field defects; examination reveals cotton-